CRISPR Gene Activation Without Cutting DNA

Abstract

Scientists demonstrated that genes can be turned back on without cutting DNA by removing chemical tags (methyl groups) that act as molecular anchors silencing gene expression. This confirms that DNA methylation actively suppresses genes — not just a passive byproduct — and opens a safer path for gene therapy, particularly for Sickle Cell disease.

Key Contributions

• Proved methyl groups are active gene silencers: removing them reactivates dormant genes; reapplying them re-silences genes
• Developed epigenetic editing approach that avoids DNA double-strand breaks entirely
• Applied to Sickle Cell disease: reactivates fetal hemoglobin gene (HBG), which produces functional oxygen-carrying proteins
• Substantially reduces cancer risk compared to traditional CRISPR cutting, which can cause unintended mutations at break sites
• Metaphor: methyl groups are "cobwebs" — brush them off and the gene comes on; the fetal globin gene is "training wheels on a kid's bike"

Methodology

• Used CRISPR machinery adapted to target and remove methyl groups at specific gene promoter regions
• No DNA strand breaks — the CRISPR system is modified to perform epigenetic editing rather than sequence editing
• Targeted the fetal globin gene (HBG) promoter, which is naturally methylated and silenced after birth
• Removing methylation at this locus reactivated fetal hemoglobin production

Results

• Successfully reactivated fetal globin gene in human cells
• When methyl groups were reapplied, genes switched off again — confirming the causal role of methylation
• Human cell studies completed; animal trials planned next
• Proof of concept for a "gentler" gene therapy with reduced off-target risks

Clinical Significance

• Traditional CRISPR for Sickle Cell (e.g., Casgevy, approved 2023) works by cutting DNA to disrupt a repressor gene — effective but carries mutation risk
• This approach offers an alternative: directly reactivate the therapeutic gene without any cuts
• Potentially applicable beyond Sickle Cell to any disease where a beneficial gene has been epigenetically silenced
• Could enable "reversible" gene therapy — effects could theoretically be undone by re-methylation

Limitations

• Currently demonstrated in cell studies only — animal trials needed before clinical translation
• Long-term durability of demethylation unknown — cells may re-methylate the target over time
• Delivery to bone marrow stem cells at scale remains a challenge (same as all gene therapies)
• Epigenetic editing is less precise than sequence editing — potential for off-target demethylation

Source: CRISPR breakthrough turns genes on without cutting DNA — UNSW Sydney